IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 3,510,000 shares, a growth of 25.4% from the February 13th total of 2,800,000 shares. Approximately 2.0% of the company's shares are short sold. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is currently 2.5 days.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fairtree Asset Management Pty Ltd purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $503,000. Wealth Enhancement Advisory Services LLC raised its holdings in IQVIA by 83.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 9,861 shares of the medical research company's stock valued at $1,938,000 after acquiring an additional 4,483 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ bought a new position in IQVIA during the 4th quarter valued at $11,478,000. PKO Investment Management Joint Stock Co acquired a new position in IQVIA during the 4th quarter worth $491,000. Finally, Mattson Financial Services LLC increased its position in shares of IQVIA by 20.9% in the 4th quarter. Mattson Financial Services LLC now owns 5,844 shares of the medical research company's stock worth $1,148,000 after purchasing an additional 1,011 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.
IQVIA Stock Up 0.9 %
NYSE:IQV traded up $1.59 during trading hours on Friday, hitting $185.85. The stock had a trading volume of 3,242,588 shares, compared to its average volume of 1,237,538. The company has a market cap of $32.77 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business has a 50 day simple moving average of $195.30 and a two-hundred day simple moving average of $209.18. IQVIA has a 1-year low of $179.28 and a 1-year high of $256.29. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts predict that IQVIA will post 10.84 EPS for the current year.
Wall Street Analyst Weigh In
IQV has been the topic of a number of recent analyst reports. UBS Group reduced their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Morgan Stanley raised their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Finally, Barclays dropped their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $249.05.
Read Our Latest Analysis on IQVIA
IQVIA Company Profile
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
